SDGR
$17.59
$-0.87 (-4.71%)-4.71%
After HoursLoading chart...
IndexN/A
Market Cap1.31B
Enterprise Value1.19B
Income$-0.06B
Sales$0.06B
EmployeesN/A
P/E-23.77
P/S5.13
P/B3.61
P/C105.42
EV/EBITDA-12.38
EV/SalesN/A
EPS (ttm)-0.74
EarningsN/A
Gross Margin55.74%
Oper. Margin-65.23%
Profit Margin-40.36%
Volume0.93M
Shs Outstand0.07B
Change-4.71%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $207.54M | $216.67M | $180.96M | $137.93M | $108.09M | $85.54M | $66.64M | $55.69M |
| Cost of Revenue | $75.46M | $75.97M | $79.93M | $72.31M | $44.62M | $36.45M | $23.70M | $15.89M |
| Gross Profit | $132.08M | $140.69M | $101.02M | $65.62M | $63.47M | $49.09M | $42.94M | $39.80M |
| Gross Margin | 63.64% | 64.93% | 55.83% | 47.57% | 58.72% | 57.39% | 64.43% | 71.46% |
| Operating Expenses | $341.38M | $318.14M | $247.84M | $177.06M | $124.39M | $87.81M | $70.91M | $58.82M |
| Operating Income | $-209.30M | $-177.45M | $-146.82M | $-111.44M | $-60.92M | $-38.72M | $-27.97M | $-19.02M |
| Operating Margin | -100.85% | -81.90% | -81.13% | -80.80% | -56.35% | -45.26% | -41.97% | -34.15% |
| Net Income | $-187.12M | $40.72M | $-149.19M | $-100.39M | $-24.46M | $-24.57M | $-28.43M | $-17.39M |
| Net Margin | -90.16% | 18.79% | -82.44% | -72.78% | -22.63% | -28.72% | -42.66% | -31.23% |
| EPS (Basic) | $-2.57 | $0.57 | $-2.10 | $-1.43 | $-0.44 | $-0.41 | $-0.59 | $-3.07 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $823.23M | $802.96M | $688.59M | $756.49M | $746.26M | $155.27M | $120.73M | $58.02M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $401.78M | $254.40M | $240.68M | $199.40M | $122.24M | $248.59M | $192.29M | $103.38M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $421.44M | $548.56M | $447.89M | $557.07M | $624.01M | $-93.36M | $-71.56M | $-45.36M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $421.44M | $548.56M | $447.89M | $557.07M | $624.01M | $-93.36M | $-71.56M | $-45.36M |
| Total Liabilities & Stockholders Equity | $823.23M | $802.96M | $688.59M | $756.49M | $746.26M | $155.27M | $120.73M | $58.02M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-187.12M | $40.72M | $-149.19M | $-100.39M | $-24.46M | $-24.57M | $-28.43M | $-17.39M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-157.37M | $-136.73M | $-119.68M | $-70.67M | $16.76M | $-26.06M | $-23.71M | $-15.31M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Generative AI in Drug Discovery: Revolutionizing Pharmaceutical Research and DevelopmentGlobeNewswire Inc. The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItBenzinga Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool My Top 3 Biotech Stocks for May 2026The Motley Fool Global Biosimulation Market Poised for Phenomenal Expansion at a CAGR of ~17% by 2034 | DelveInsightGlobeNewswire Inc. Materials Informatics Market Size to Hit USD 736.71 Million by 2035GlobeNewswire Inc. Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtThe Motley Fool AI Healthcare Boom Gains Speed as Regulators and Innovators AlignBenzinga
Show 12 more stories
3 Momentum Stocks That Could Soar Post-Market VolatilityInvesting.com Biosimulation Industry Forecast, 2029: Analysis of Case Studies, Market Dynamics, Regional Growth Trends, Regulatory Landscape, Value Chain, and Competitive IntelligenceGlobeNewswire Inc. Material Informatics Market Share is Growing at 16.4% CAGR to Hit USD 705.21 million by 2034 | PMRGlobeNewswire Inc. Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: DetailsBenzinga What Analysts Are Saying About Schrodinger Stock - BenzingaBenzinga What's the Difference Between Biotech Stocks and TechBio Stocks?The Motley Fool Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research Billionaire Bill Gates Has 35% of His Portfolio Invested in These 2 Artificial Intelligence (AI) Stocks: Are They No-Brainer Buys?The Motley Fool Critical Insights From Schrodinger Analyst Ratings: What You Need To KnowBenzinga Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionBenzinga Why Okta Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving PremarketBenzinga Shoals Technologies Posts Weak Q4 Results, Joins Butterfly Network, Schrödinger And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionBenzinga
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Discover more
You may be interested in